Cargando…

CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma

INTRODUCTION: The combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaofang, Srinivasan, Priya, Basu, Mousumi, Zimmerman, Talia, Li, Samuel, Wang, Yin, Zheng, Pan, Liu, Yang, Sandler, Anthony David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279976/
https://www.ncbi.nlm.nih.gov/pubmed/37346042
http://dx.doi.org/10.3389/fimmu.2023.1176370
_version_ 1785060705339179008
author Wu, Xiaofang
Srinivasan, Priya
Basu, Mousumi
Zimmerman, Talia
Li, Samuel
Wang, Yin
Zheng, Pan
Liu, Yang
Sandler, Anthony David
author_facet Wu, Xiaofang
Srinivasan, Priya
Basu, Mousumi
Zimmerman, Talia
Li, Samuel
Wang, Yin
Zheng, Pan
Liu, Yang
Sandler, Anthony David
author_sort Wu, Xiaofang
collection PubMed
description INTRODUCTION: The combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related adverse events (irAEs) associated with induction of potent immunity must be addressed. The CD24-Siglec 10/G interaction is an innate checkpoint that abrogates inflammatory responses to molecules released by damaged cells, but its role in cancer immunology is not well defined. We investigate irAEs of an effective whole cell neuroblastoma vaccine and subsequently the effect of CD24-Fc, a CD24 and Fc fusion protein, on both the vaccine efficacy and induced irAEs in a mouse neuroblastoma model. METHODS: To test whether the whole tumor cell vaccination leads to autoimmune responses in other organ systems we harvested lung, heart, kidney and colon from naïve mice (n=3), unvaccinated tumor only mice (n=3), and vaccinated mice with CD24 Fc (n=12) or human IgG-Fc control (n=12) after tumor inoculation and vaccination therapy at day 30. The Immune cell infiltrates and immunogenic pathway signatures in different organ systems were investigated using NanoString Autoimmune Profiling arrays. Nanostring RNA transcript results were validated with immunohistochemistry staining. RESULTS: The whole tumor cell vaccine combined with immune checkpoint therapy triggers occult organ specific immune cell infiltrates, primarily in cardiac tissue and to a lesser extent in the renal and lung tissue, but not in the colon. CD24-Fc administration with vaccination partially impedes anti-tumor immunity but delaying CD24-Fc administration after initial vaccination reverses this effect. CD24-Fc treatment also ameliorates the autoimmune response induced by effective tumor vaccination in the heart. DISCUSSION: This study illustrates that the combination of Myc suppressed whole tumor cell vaccination with checkpoint inhibitors is an effective therapy, but occult immune infiltrates are induced in several organ systems in a mouse neuroblastoma model. The systemic administration of CD24-Fc suppresses autoimmune tissue responses, but appropriate timing of administration is critical for maintaining efficacy of the therapeutic vaccine.
format Online
Article
Text
id pubmed-10279976
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102799762023-06-21 CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma Wu, Xiaofang Srinivasan, Priya Basu, Mousumi Zimmerman, Talia Li, Samuel Wang, Yin Zheng, Pan Liu, Yang Sandler, Anthony David Front Immunol Immunology INTRODUCTION: The combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related adverse events (irAEs) associated with induction of potent immunity must be addressed. The CD24-Siglec 10/G interaction is an innate checkpoint that abrogates inflammatory responses to molecules released by damaged cells, but its role in cancer immunology is not well defined. We investigate irAEs of an effective whole cell neuroblastoma vaccine and subsequently the effect of CD24-Fc, a CD24 and Fc fusion protein, on both the vaccine efficacy and induced irAEs in a mouse neuroblastoma model. METHODS: To test whether the whole tumor cell vaccination leads to autoimmune responses in other organ systems we harvested lung, heart, kidney and colon from naïve mice (n=3), unvaccinated tumor only mice (n=3), and vaccinated mice with CD24 Fc (n=12) or human IgG-Fc control (n=12) after tumor inoculation and vaccination therapy at day 30. The Immune cell infiltrates and immunogenic pathway signatures in different organ systems were investigated using NanoString Autoimmune Profiling arrays. Nanostring RNA transcript results were validated with immunohistochemistry staining. RESULTS: The whole tumor cell vaccine combined with immune checkpoint therapy triggers occult organ specific immune cell infiltrates, primarily in cardiac tissue and to a lesser extent in the renal and lung tissue, but not in the colon. CD24-Fc administration with vaccination partially impedes anti-tumor immunity but delaying CD24-Fc administration after initial vaccination reverses this effect. CD24-Fc treatment also ameliorates the autoimmune response induced by effective tumor vaccination in the heart. DISCUSSION: This study illustrates that the combination of Myc suppressed whole tumor cell vaccination with checkpoint inhibitors is an effective therapy, but occult immune infiltrates are induced in several organ systems in a mouse neuroblastoma model. The systemic administration of CD24-Fc suppresses autoimmune tissue responses, but appropriate timing of administration is critical for maintaining efficacy of the therapeutic vaccine. Frontiers Media S.A. 2023-06-06 /pmc/articles/PMC10279976/ /pubmed/37346042 http://dx.doi.org/10.3389/fimmu.2023.1176370 Text en Copyright © 2023 Wu, Srinivasan, Basu, Zimmerman, Li, Wang, Zheng, Liu and Sandler https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wu, Xiaofang
Srinivasan, Priya
Basu, Mousumi
Zimmerman, Talia
Li, Samuel
Wang, Yin
Zheng, Pan
Liu, Yang
Sandler, Anthony David
CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
title CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
title_full CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
title_fullStr CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
title_full_unstemmed CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
title_short CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
title_sort cd24-fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279976/
https://www.ncbi.nlm.nih.gov/pubmed/37346042
http://dx.doi.org/10.3389/fimmu.2023.1176370
work_keys_str_mv AT wuxiaofang cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT srinivasanpriya cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT basumousumi cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT zimmermantalia cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT lisamuel cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT wangyin cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT zhengpan cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT liuyang cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma
AT sandleranthonydavid cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma